Patents Examined by Danah Al-Awadi
  • Patent number: 11229606
    Abstract: Extended release pyridostigmine dosage forms, suitable for maintaining stable plasma concentrations with reduced or minimized initial burst release/dose dumping of pyridostigmine, are provided. The dosage forms include matrix tablets, gastroretentive tablets, and pellets, the latter being suitable for dosing in capsules, tablets, and sachets, as well as for sprinkling on foodstuffs. The disclosure also provides methods for improving patient compliance by administering once-a-day extended release pyridostigmine bromide dosage forms that provide a superior controlled drug release.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: January 25, 2022
    Assignee: Amneal Complex Products Research LLC
    Inventors: Siva Ram Kiran Vaka, Namdev B. Shelke, Dipen Desai, Wantanee Phuapradit, Navnit H. Shah
  • Patent number: 11202762
    Abstract: The present invention relates to a drug delivery system comprising a core and a shell in which the core comprises a hydrolytically degradable polymer X which polymer backbone comprises pendant ester and acid functionalities and in which the shell comprises a hydrolytic degradable polymer Y. The hydrolytic degradable polymers X and Y are different polymers. Polymer X further comprises amino-acids in the polymer backbone and degrades via zero order degradation kinetics for a period of at least 3 months. Polymer Y degrades via auto-acceleration degradation kinetics.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: December 21, 2021
    Assignee: DSM IP ASSETS B.V.
    Inventors: George Mihov, Guy Draaisma, Silvana Rensina Antonnietta Di Silvestre, Tristan Handels
  • Patent number: 11173104
    Abstract: A composition suitable for application as a nail polish, the composition comprising: an alcohol solvent; ethylcellulose, in an amount that is about 1.0% by weight of the final composition; a film forming agent that includes maleic acid monobutyl ester-vinyl methyl ether copolymer, and maleic acid monoethyl ester-vinyl methyl ether copolymer, in an amount that is at least 40% by weight of the final composition; isostearyl alcohol, in an amount that is about 3.0% by weight of the final composition; a plasticizer in the form of a citric acid ester, in art amount that is about 1.0% by weight of the final composition; a colorant and a fragrance. This composition is suitable for application to a human nail.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: November 16, 2021
    Inventor: Yoram Fishman
  • Patent number: 11173229
    Abstract: The present invention provides a method for preparing an injectable thermosensitive chitosan/TEMPO-oxidized cellulose nanofibers hydrogel. The injectable thermosensitive chitosan/TEMPO-oxidized cellulose nanofibers hydrogel exhibits superior biocompatibility through addition of TEMPO-oxidized cellulose nanofibers, and excellent cell proliferation and bone regeneration through cellular interaction, and is gelled in vivo, thus being highly useful as a filler for wound healing and bone regeneration. In addition, the injectable thermosensitive chitosan/TEMPO-oxidized cellulose nanofibers hydrogel exhibits excellent porosity, has an interconnected structure and is thermogelling, based on thermosensitivity of undergoing a sol-gel transition depending on temperature, thus inducing rapid gelation in vivo and facilitating bone regeneration upon implantation in vivo.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: November 16, 2021
    Assignees: SOONCHUNHYANG UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION, NATIONAL INSTITUTE OF FOREST SCIENCE
    Inventors: Byong Taek Lee, Sun-Young Lee, Trang Nguyen Ho Minh, Celine Abueva, Sang-Jin Chun, Jae-Gyoung Gwon
  • Patent number: 11147833
    Abstract: The object of the present invention is to provide a therapeutic agent for hyperphosphatemia capable sufficiently decreasing a serum phosphorus concentration with a small dose. The present invention provides a therapeutic agent for hyperphosphatemia, which comprises, as an active ingredient, a particle containing certain crosslinked polymer (preferably crosslinked polyallylamine).
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: October 19, 2021
    Assignees: FUJIFILM Corporation, Kyowa Kirin Co., Ltd.
    Inventors: Shinsuke Tokuoka, Hayato Yoshida, Yuichiro Kondo
  • Patent number: 11118144
    Abstract: The invention provides formulations and a process for disinfection, cleansing, and establishing a residual biostatic surface protection for dentures and removable oral appliances. These appliances include complete and partial dentures, removable dental applications, and other products used in an individual's mouth.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: September 14, 2021
    Assignee: CLEARSTREAM TECHNOLOGIES, LLC
    Inventors: Anthony L Daddona, III, James Praechtl, Daniel Spagnoli, William Spilfogel, Simpson E. Adams, III, Rebecca L Lister
  • Patent number: 11110063
    Abstract: Disclosed herein are solid compositions that comprise sincalide and are storage stable and which lack a buffer, and optionally, also lack a surfactant/solubilizer, wherein such compositions are storage stable. Also disclosed herein are liquid compositions that comprise sincalide, wherein such compositions are storage stable, and may lack buffer and/or surfactant/solubilizer. Also provided are methods of making and administering the solid or liquid storage stable compositions to a patient in need of, e.g., for the treatment, prevention, and/or diagnosis of gall bladder- and/or pancreatic disorders; or other diagnostic imaging.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: September 7, 2021
    Assignee: MAIA Pharmaceuticals, Inc.
    Inventor: Srikanth Sundaram
  • Patent number: 11097007
    Abstract: An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s?1 and having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1,000 s?1, as measured.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: August 24, 2021
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Daiki Kaneko, Takakuni Matsuda, Yusuke Hoshika
  • Patent number: 11097031
    Abstract: A freshening composition is provided. The composition includes at least one particle, and an aqueous carrier. The composition includes a polysaccharide system having a first polysaccharide and a second polysaccharide. The first polysaccharide is xanthan gum and the second polysaccharide is selected from the group consisting of konjac gum, locust bean gum, tara gum, and combinations thereof. The composition may include an unencapsulated perfume.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: August 24, 2021
    Assignee: The Procter & Gamble Company
    Inventors: Matthew Lawrence Lynch, Carla Jean Colina, Steven Anthony Horenziak, Brandon Philip Illie, Yonas Gizaw, Yiping Sun, Joana Andreia Lameiras Domingues, Susana Fernandez Prieto, Abel Jerez Gomez
  • Patent number: 11083881
    Abstract: A method for increasing permeability of a cellular layer of epithelial cells includes contacting the cellular layer with a nanostructured surface including a plurality of first nanostructures arranged thereon and projecting outward therefrom. A fractal dimension of the plurality of nanostructures is greater than 1. The permeability of the cellular layer by a compound is increased as compared to the permeability of the cellular layer prior to contact with the surface.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: August 10, 2021
    Assignee: SORRENTO THERAPEUTICS, INC.
    Inventor: Russell Frederick Ross
  • Patent number: 11071717
    Abstract: A bandage for delivering an anesthetic through a patient's skin at the site of a hypodermic injection prior to the administration of the hypodermic injection to alleviate pain due to the injection.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: July 27, 2021
    Inventor: Ana R. Olivero
  • Patent number: 11071786
    Abstract: A dermal skin protectant and carrier comprising a combination of two different viscosity dimethicone components, wherein the difference between the two different viscosity dimethicone components is about 2.0 million cP or greater; and comprising at least one active ingredient.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: July 27, 2021
    Assignee: Inspired Material Solutions, LLC
    Inventor: Mark A. Latta
  • Patent number: 11058773
    Abstract: There is provide an extended release dosage form comprising a release modifying excipient comprising high amylose starch, cross-linked hydroxypropylated amylopectin, and a pre-gelatinized common starch; wherein the release modifying excipient is substantially free of crosslinks between amylose and amylopectin and substantially free of crosslinks between amylose and amylose. It has been found that the extended release properties of conventional cross-linked high amylose starches (e.g., Contramid®) can be reproduced by intimately mixing i) cross-linked chemically modified amylopectin; ii) a high amylose, non-chemically modified starch and; iii) a pre-gelatinized common starch. Producing a release modifying excipient in this way means that no chemical cross linking between (a) amylose and amylopectin or (b) amylose and amylose has occurred—properties heretofore considered vital for Contramid® function.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: July 13, 2021
    Assignee: Altus Formulation Inc.
    Inventors: Marc Lemieux, Bradut Mitrasca, Sonia Gervais, Damon Smith
  • Patent number: 11046737
    Abstract: The present invention provides silk fibroin micro-particles having a high crystallinity index (1.3-1.5) and low sphericity index (?0.01) and a process for the preparation thereof. The high crystallinity index confers longer degradation periods to the instant silk fibroin micro-particles, therefore facilitating their use in biomedical applications.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: June 29, 2021
    Assignee: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
    Inventors: Anuya Amol Nisal, Premnath Venugopalan, Bhakti Dnyaneshwar Khude
  • Patent number: 11045429
    Abstract: Network materials which exhibit both shear thinning and self-healing properties are disclosed. The networks contain particles and gel-forming compounds. The networks are useful for a variety of biomedical uses, including drug delivery.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: June 29, 2021
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Eric A. Appel, Mark W. Tibbitt, Robert S. Langer
  • Patent number: 11007140
    Abstract: The invention relates to a method for producing a drug delivery device, which has a body comprising a siloxane-based elastomer and at least one active agent. The method comprises applying adhesive material, which comprises non-cured siloxane based elastomer, into a contact with the body and curing the said adhesive material by subjecting it to radiation energy from a laser source. The invention relates also to a drug delivery device manufactured according to the method.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: May 18, 2021
    Assignee: Bayer OY
    Inventors: Svante Holmberg, Heikki Lyytikäinen, Christine Talling, Saara Ruotsalainen, Petri Laakso
  • Patent number: 10987405
    Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: April 27, 2021
    Assignee: Coherus BioSciences, Inc.
    Inventors: Mark Manning, Brian Murphy
  • Patent number: 10987284
    Abstract: An improved hair color formulation treats hair to provide volume, viscosity, color and hair follicle stimulation. The color formulation is appointed to be used in hair products, and comprises a natural color agent and at least one agent providing anti-dihydrotestosterone (DHT) effects. Hair products include styling products, cleansing products, concealment products, and dying products. In one embodiment, the formulation comprises an aqueous emulsion, at least one hydrocarbon, at least one thickening agent, at least one humectant, at least one emollient, at least one fatty acid ester, and at least one agent providing anti-dihydrotestosterone (DHT) effects, such as caffeine, and at least one color agent. Preservatives, fibers and further treatments for male/female pattern baldness may also be added to the composition. Natural colorants are added to the hair color formulation to provide temporary coloring in addition to enhanced volume, viscosity and hair follicle stimulation.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: April 27, 2021
    Inventor: Michael V. Greene
  • Patent number: 10980885
    Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: April 20, 2021
    Assignee: Coherus Biosciences, Inc.
    Inventors: Mark Manning, Brian Murphy
  • Patent number: 10980884
    Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: April 20, 2021
    Assignee: Coherus Biosciences, Inc.
    Inventors: Mark Manning, Brian Murphy